CN108516923B - A series of alkene terpenoids and its preparation method and application - Google Patents
A series of alkene terpenoids and its preparation method and application Download PDFInfo
- Publication number
- CN108516923B CN108516923B CN201810494741.8A CN201810494741A CN108516923B CN 108516923 B CN108516923 B CN 108516923B CN 201810494741 A CN201810494741 A CN 201810494741A CN 108516923 B CN108516923 B CN 108516923B
- Authority
- CN
- China
- Prior art keywords
- alkene
- eluent
- preparation
- methanol
- terpene compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/74—Separation; Purification; Use of additives, e.g. for stabilisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/02—Acyclic alcohols with carbon-to-carbon double bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D301/00—Preparation of oxiranes
- C07D301/32—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/14—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by free hydroxyl radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides the preparation method of serial alkene terpenoid is provided, belongs to edible and medicinal fungi and co-culture prepare compound technical field.Trametes robinioplila and oyster mushroom co-cultivation are obtained into the novel serial alkene terpenoid of structure feature, can effectively inhibit Candida albicans, Cryptococcus neoformans, staphylococcus aureus, (apple) rotten pathogenic bacteria and human lung cancer cell line A549.Embodiment statistics indicate that, series alkene terpenoid made from preparation method provided by the invention has certain rejection ability to Candida albicans, Cryptococcus neoformans, (apple) rotten pathogenic bacteria and staphylococcus aureus, and has good inhibitory effect to human lung cancer cell line A549.
Description
Technical field
The present invention relates to edible and medicinal fungis to co-culture prepare compound technical field more particularly to a series of alkene terpenes
Close object and its preparation method and application.
Background technique
Disable/lethality height, poor prognosis, therapeutic agent it is extremely limited etc. due to, mankind invasion pathomycete is drawn
The systemic infection of hair has seriously threatened human health safety.In known 625 kinds of pathogenic fungus, by aspergillus, beads
Infected with 300,000,000 caused by category, hidden ball category, hair tinea category.Antibacterials currently used for treating monilial infection mainly have polyenoid
Class, azole, pyrimidine homologue, echinocandin class.Wherein it is used for the amphomoronal and imidazoles for the treatment of system fungal infection
And the drugs such as terbinafine for epidermis fungal infection, there is field of activity, toxicity, adverse reaction and drug resistances etc.
Problem.Fungal infection increase sharply and the shortage of active drug, so that the research and development of novel antifungal drugs is seemed outstanding
It is urgent.
Microorganism is the important sources of natural active compound.However, having pharmaceutical activity in recent years and can make
Discovery process for the novel natural products of antibiotic is slow.Natural active compound such as is prepared using single culture, trametes robinioplila is
A kind of civil medicinal fungi to treating cancer and inflammation, is grown on ancient middle Chinese scholar tree, scientific name Trametes
Robimiophila Murr., the entitled Chinese scholartree bolt bacterium of Chinese, belongs to Basidiomycotina (Basidiomycotina), Polyporaceae
(Polyporaccac), Trametes.It can control wind, blood-breaking, beneficial power.Trametes robinioplila fructification contains the various actives substances such as fungi polysaccharide,
Have the effects that inhibit tumour growth, induces internal cytokine profiles, improves immunity of organisms.
Summary of the invention
In view of this, the purpose of the present invention is to provide serial alkene terpenoids and its preparation method and application.This hair
Trametes robinioplila and oyster mushroom co-culture by the serial alkene terpenoid preparation method of bright offer to be obtained six kinds and can effectively inhibit
Candida albicans, Cryptococcus neoformans and staphylococcus aureus, (apple) rotten pathogenic bacteria and human lung cancer cell line A549.
In order to achieve the above-mentioned object of the invention, the present invention the following technical schemes are provided:
The preparation method of serial alkene terpene compound, comprising the following steps:
(1) trametes robinioplila is inoculated on seed culture medium and is cultivated, obtain trametes robinioplila seed liquor, the preservation of the trametes robinioplila is compiled
Number be CGMCC No.15274；
Oyster mushroom is inoculated on seed culture medium and is cultivated, oyster mushroom seed liquor is obtained；
(2) the trametes robinioplila seed liquor that the step (1) obtains is mixed with oyster mushroom seed liquor and is co-cultured, obtain total training
Nutrient solution；
(3) it is extracted with the co-culture media that ethyl acetate obtains the step (2), obtains removing after extract liquor molten
Agent obtains medicinal extract；
It is successively 5:1 and the petroleum ether-ethyl acetate eluent of 1:1, volume ratio 20:1,10:1,5:1 with volume ratio,
The methylene chloride-methanol eluent of 1:1,0:1, chromatograph medicinal extract, respectively obtain 7 chromatographic solutions, are successively defined as first
~layer 7 analyses liquid；
The first medium pressure chromatography preparation is carried out with methanol-water solution to the third chromatographic solution, obtains the first separating liquid, it is right
First separating liquid successively carries out gel column chromatography point with the methanol-water eluent that volume ratio is 1:1,7:3,9:1 and 1:0
From it is the alkene terpene containing structure shown in Formulas I that it is obtained after separation, which to carry out gel column chromatography, for 7:3 methanol-water eluent for volume ratio
The eluent of compound carries out the first high pressure preparation to the eluent of the alkene terpene compound containing structure shown in I, obtains
Alkene terpene compound with structure shown in Formulas I, the first high pressure preparation condition: chromatographic column: YMC-Pack ODS-A C18, flow velocity:
5mL/min；Mobile phase A: ultrapure water；Mobile phase B: methanol；Gradient: 0-25min, 25%-40%B；25-60min, 40-
100%B；It is containing formula that it is obtained after separation, which to carry out gel column chromatography, for the methanol-water eluent of 1:1,9:1 and 1:0 for volume ratio
The eluent of the alkene terpene compound of structure shown in IV, to the eluent of the alkene terpene compound containing structure shown in formula IV into
Row purifying, obtains the alkene terpene compound with structure shown in formula IV；
The second medium pressure chromatography preparation is carried out with methanol-water solution to the 4th chromatographic solution, obtains the second separating liquid, it is right
Second separating liquid successively carries out gel column chromatography point with the methanol-water eluent that volume ratio is 1:1,7:3,9:1 and 1:0
From it is the alkene terpene containing structure shown in II that it is obtained after separation, which to carry out gel column chromatography, for 9:1 methanol-water eluent for volume ratio
The eluent of compound carries out the second high pressure to the eluent of the alkene terpene compound containing structure shown in Formula II and is prepared into
To the alkene terpene compound with structure shown in Formula II, the second high pressure preparation condition are as follows: column YMC-Pack ODS-A C18 is prepared,
Flow velocity: 5mL/min；Mobile phase A: ultrapure water；Mobile phase B: methanol；It is isocratic: 0-50min, 45%B；Volume ratio is 7:3 first
It is the alkene terpene compound containing structure shown in formula III, V and VI that it is obtained after separation, which to carry out gel column chromatography, for alcohol-water elution
Eluent carries out high performance liquid chromatography separation difference to the eluent of the alkene terpene compound containing structure shown in formula III, V and VI
Obtain having the alkene terpene compound of structure shown in formula III, V and VI, high-efficient liquid phase chromatogram condition are as follows: prepare column YMC-Pack
ODS-A C18, flow velocity: 5mL/min；Mobile phase A: ultrapure water；Mobile phase B: methanol；Gradient: 0-20min, 25%-50%B；
20-50min, 50%-100%B；
Preferably, in the step (1) seed culture medium independently include following concentration component: 8~12g/ of glucose
L, 1~3g/L of peptone, 0.8~1.2g/L of potassium dihydrogen phosphate, 0.3~0.5g/L of magnesium sulfate, the water of surplus.
Preferably, the amount ratio of the trametes robinioplila and seed culture medium be in 200mL culture medium containing 6~8 block specifications be 5cm
The trametes robinioplila mycelia of size
The amount ratio of the oyster mushroom and seed culture medium be in 200mL culture medium containing 8~10 block specifications be 5cm size
Hypha of Pleurotus ostreatus.
Preferably, the inoculum concentration of trametes robinioplila seed liquor is 50~70% in the step (2).
Preferably, the temperature of the culture in the step (1) and the co-cultivation in step (2) independently is 24~28 DEG C.
Preferably, the incubation time of trametes robinioplila is 5~8 in the step (1), and the incubation time of oyster mushroom is 4~6 days.
Preferably, the time co-cultured in the step (2) is 15~25 days.
Serial alkene terpene compound, have Formulas I~Formula IV it is any shown in structure:
The present invention also provides series alkene terpenoids made from the preparation method described in above-mentioned technical proposal or above-mentioned
Serial alkene terpenoid inhibits the application in bacterium bacterium, human pathogenic fungi and phytopathogenic fungi drug in preparation.
The present invention also provides series alkene terpenoids made from the preparation method described in above-mentioned technical proposal or above-mentioned
Serial alkene terpenoid preparation treating cancer drug in application.
The present invention provides the preparation methods of serial alkene terpenoid, and trametes robinioplila and oyster mushroom co-cultivation are obtained structure
The novel serial alkene terpenoid of feature, can effectively inhibit Candida albicans, Cryptococcus neoformans, staphylococcus aureus,
(apple) rotten pathogenic bacteria and human lung cancer cell line A549.Embodiment statistics indicate that, preparation method provided by the invention be made
Serial alkene terpenoid have one to Candida albicans, Cryptococcus neoformans and staphylococcus aureus, (apple) rotten pathogenic bacteria
Fixed rejection ability, and there is good inhibitory effect to human lung cancer cell line A549.
Biological deposits explanation:
Chinese scholartree keyhole bacterium (Trametes robiniophila) was deposited in Chinese microorganism strain on 01 16th, 2018
Preservation administration committee common micro-organisms center, address are Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3, and the Chinese Academy of Sciences is micro-
Biological study institute；Biological deposits number is CGMCC No.15274.
Detailed description of the invention
The present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments.
Fig. 1 is structure alkene terpene compound shown in Formulas I in the embodiment of the present invention1H-NMR spectrum；
Fig. 2 is structure alkene terpene compound shown in Formulas I in the embodiment of the present invention13CNMR spectrogram；
Fig. 3 is the MS/MS spectrogram of structure alkene terpene compound shown in Formulas I in the embodiment of the present invention；
Fig. 4 is the MS/MS spectrogram of structure alkene terpene compound shown in formula IV in the embodiment of the present invention；
Fig. 5 is structure alkene terpene compound shown in Formula II in the embodiment of the present invention1H-NMR spectrum；
Fig. 6 is structure alkene terpene compound shown in Formula II in the embodiment of the present invention13CNMR spectrogram；
Fig. 7 is the MS/MS spectrogram of structure alkene terpene compound shown in Formula II in the embodiment of the present invention；
Fig. 8 is structure alkene terpene compound shown in formula III in the embodiment of the present invention1H-NMR spectrum；
Fig. 9 is structure alkene terpene compound shown in formula III in the embodiment of the present invention13CNMR spectrogram；
Figure 10 is the MS/MS spectrogram of structure alkene terpene compound shown in formula III in the embodiment of the present invention；
Figure 11 is the LC-MS spectrogram of structure system terpene compound shown in Formula V in the embodiment of the present invention；
Figure 12 is the LC-MS spectrogram of structure alkene terpene compound shown in Formula IV in the embodiment of the present invention.
Specific embodiment
The present invention provides the preparation methods of serial alkene terpene compound, comprising the following steps:
(1) trametes robinioplila is inoculated on seed culture medium and is cultivated, obtain trametes robinioplila seed liquor, the preservation of the trametes robinioplila is compiled
Number be CGMCC No.15274；
Oyster mushroom is inoculated on seed culture medium and is cultivated, oyster mushroom seed liquor is obtained；
(2) the trametes robinioplila seed liquor that the step (1) obtains is mixed with oyster mushroom seed liquor and is co-cultured, obtain total training
Nutrient solution；
(3) it is extracted with the co-culture media that ethyl acetate obtains the step (2), obtains removing after extract liquor molten
Agent obtains medicinal extract；
It is successively 5:1 and the petroleum ether-ethyl acetate eluent of 1:1, volume ratio 20:1,10:1,5:1 with volume ratio,
The methylene chloride-methanol eluent of 1:1,0:1, chromatograph medicinal extract, respectively obtain 7 chromatographic solutions, are successively defined as first
~layer 7 analyses liquid；
The first medium pressure chromatography preparation is carried out with methanol-water solution to the third chromatographic solution, obtains the first separating liquid, it is right
First separating liquid successively carries out gel column chromatography point with the methanol-water eluent that volume ratio is 1:1,7:3,9:1 and 1:0
From it is the alkene terpene containing structure shown in Formulas I that it is obtained after separation, which to carry out gel column chromatography, for 7:3 methanol-water eluent for volume ratio
The eluent of compound carries out the first high pressure preparation to the eluent of the alkene terpene compound containing structure shown in I, obtains
Alkene terpene compound with structure shown in Formulas I, the first high pressure preparation condition: chromatographic column: YMC-Pack ODS-A C18, flow velocity:
5mL/min；Mobile phase A: ultrapure water；Mobile phase B: methanol；Gradient: 0-25min, 25%-40%B；25-60min, 40-
100%B；It is containing formula that it is obtained after separation, which to carry out gel column chromatography, for the methanol-water eluent of 1:1,9:1 and 1:0 for volume ratio
The eluent of the alkene terpene compound of structure shown in IV, to the eluent of the alkene terpene compound containing structure shown in formula IV into
Row purifying, obtains the alkene terpene compound with structure shown in formula IV；
4th chromatographic solution is carried out to press separation in second with methanol-water solution, the second separating liquid is obtained, to described
Second separating liquid successively carries out gel column chromatography separation, body with the methanol-water eluent that volume ratio is 1:1,7:3,9:1 and 1:0
Product is the alkene terpene compound containing structure shown in II than it is obtained after separation to carry out gel column chromatography for 9:1 methanol-water eluent
Eluent, carry out the second high pressure to the eluent of the alkene terpene compound containing structure shown in Formula II and be prepared to have
The alkene terpene compound of structure shown in Formula II, the second high pressure preparation condition are as follows: prepare column YMC-Pack ODS-A C18, flow velocity:
5mL/min；Mobile phase A: ultrapure water；Mobile phase B: methanol；It is isocratic: 0-50min, 45%B；Volume ratio is that 7:3 methanol-water is washed
De- liquid carry out gel column chromatography it is obtained after separation be the alkene terpene compound containing structure shown in formula III, V and VI eluent,
High performance liquid chromatography separation is carried out to the eluent of the alkene terpene compound containing structure shown in formula III, V and VI and respectively obtains tool
There are the alkene terpene compound of structure shown in formula III, V and VI, high-efficient liquid phase chromatogram condition are as follows: prepare column YMC-Pack ODS-A
C18, flow velocity: 5mL/min；Mobile phase A: ultrapure water；Mobile phase B: methanol；Gradient: 0-20min, 25%-50%B；20-
50min, 50%-100%B；
Trametes robinioplila is inoculated on seed culture medium and cultivates by the present invention, obtains trametes robinioplila seed liquor, the preservation of the trametes robinioplila
Number is CGMCCNo.15274；Oyster mushroom is inoculated on seed culture medium and is cultivated, oyster mushroom seed liquor is obtained.In the present invention
In, the seed culture medium independently preferably includes the component of following concentration: 8~12g/L of glucose, 1~3g/L of peptone,
0.8~1.2g/L of potassium dihydrogen phosphate, 0.3~0.5g/L of magnesium sulfate, the water of surplus, more preferably 10g/L, peptone 2g/L, phosphorus
Acid dihydride potassium 1g/L, magnesium sulfate 0.5g/L, the water of surplus.
In the present invention, the trametes robinioplila preferably uses 6~8 block specifications to train for the trametes robinioplila mycelia of 5cm size and 200mL
Feeding base is cultivated, the oyster mushroom preferably use 8~10 block specifications be the hypha of Pleurotus ostreatus of 5cm size and 200mL culture medium into
Row culture.
In the present invention, the trametes robinioplila is preferably obtained from trametes robinioplila solid seed plate；The oyster mushroom is preferably from oyster mushroom
It is obtained in solid seed plate.
In the present invention, the incubation time of the trametes robinioplila is preferably 5~8 days, and more preferably 6~7 days；The oyster mushroom
Incubation time is preferably 4~6 days, and more preferably 5 days.In the present invention, the incubation time of the trametes robinioplila than oyster mushroom culture when
Between it is 1~2 day preferably more.In the present invention, it is preferred to carry out the culture of trametes robinioplila in advance.
In the present invention, the culture independently preferably carries out in conical flask；The culture independently preferably exists
It is cultivated under natural lighting.
After obtaining trametes robinioplila seed liquor and oyster mushroom seed liquor, the present invention mixes the trametes robinioplila seed liquor with oyster mushroom seed liquor
It is co-cultured, obtains co-culture media.In the present invention, the inoculum concentration of the trametes robinioplila seed liquor is preferably 50~70%, more excellent
It is selected as 60~65%.
In the present invention, independently preferably 24~28 DEG C of the temperature of the culture and co-cultivation, more preferably 25~27
℃。
In the present invention, the time of the co-cultivation is preferably 15~25 days, and more preferably 20 days.In the present invention, institute
Co-cultivation is stated preferably to carry out under natural lighting.In the present invention, the seed liquor individually cultivated need to only be mixed when the co-cultivation
Conjunction is not required to supplement fresh culture.
In the present invention, the culture and co-cultivation independently carry out preferably in shaking table.In the present invention, described to shake
The revolving speed of bed is 160rpm.
After obtaining co-culture media, the present invention extracts the co-culture media with ethyl acetate, removes after obtaining extract liquor
Solvent is removed, medicinal extract is obtained；In the present invention, the volume ratio of the ethyl acetate and co-culture media is preferably 1~3:1. more preferable
For 2:1.In the present invention, after the extraction, upper layer of extraction liquid is taken.The mode that solvent is removed described in degree of the present invention is not special
Restriction, by the way of removing solvent well known to those skilled in the art, specifically, as be evaporated under reduced pressure.
In the present invention, the solvent content in the medicinal extract is preferably 8%.
After obtaining medicinal extract, the present invention is successively 5:1 with volume ratio and the petroleum ether-ethyl acetate eluent of 1:1, volume
Than for 20:1,10:1,5:1, the methylene chloride-methanol eluent of 1:1,0:1 chromatograph medicinal extract, 7 layers are respectively obtained
Liquid is analysed, first~layer 7 analysis liquid is followed successively by；
In the present invention, the chromatographic column used that chromatographs is preferably silicagel column.In the present invention, the silicagel column
Specification is preferred are as follows: 25 × 520mm, Tianjin Bonaaijieer Technology Co., Ltd, 200~300 mesh.In the present invention, the layer
The flow velocity of eluent is preferably 6mL/min when analysis.
After the chromatography, the present invention carries out the first medium pressure chromatography preparation to the third chromatographic solution with methanol-water solution,
The first separating liquid is obtained, is successively the methanol-water eluent of 1:1,7:3,9:1 and 1:0 with volume ratio to first separating liquid
Carry out gel column chromatography separation, volume ratio be 7:3 methanol-water eluent carry out gel column chromatography it is obtained after separation be containing
The eluent of the alkene terpene compound of structure shown in Formulas I carries out the eluent of the alkene terpene compound containing structure shown in I
The preparation of first high pressure, obtains the alkene terpene compound with structure shown in Formulas I, the first high pressure preparation condition: chromatographic column: YMC-
Pack ODS-A C18, flow velocity: 5mL/min；Mobile phase A: ultrapure water；Mobile phase B: methanol；Gradient elution program: 0-25
Min, 25%-40%B；25-60min, 40-100%B；The methanol-water eluent that volume ratio is 1:1,9:1,1:0 carries out gel
What is obtained after pillar layer separation is the eluent of the alkene terpene compound containing structure shown in formula IV, to described containing shown in formula IV
The eluent of the alkene terpene compound of structure is purified, and the alkene terpene compound with structure shown in formula IV is obtained；
In the present invention, the condition of the first medium pressure chromatography preparation is preferred are as follows: Ai Jieer Flash splitter:
CO140080-0, eluent: methanol-water solution carries out, methanol (v/v, %), 15-40%, 8min；40-100%, 82min,
Flow velocity 30mL/min.
In the present invention, the filler that the gel column chromatography separation uses is hydroxypropyl sephadex (LH-20).?
In the present invention, the eluent of the gel column chromatography separation is preferred are as follows: methanol-water (1:1,7:3,9:1 and 1:0), flow velocity is preferred
For 0.3mL/min.
In the present invention, the condition that the eluent of the alkene terpene compound to described containing structure shown in formula IV is purified
It is preferred that are as follows: Ai Jieer Flash splitter: CO140080-0, eluent: methanol-water solution carries out, methanol %, 15-30%,
10min；30-70%, 82min, flow velocity 30mL/min.In the present invention, the component collected within 55~59min is available
Alkene terpene compound containing structure shown in formula IV.
After the chromatography, the present invention carries out the second medium pressure chromatography preparation to the 4th chromatographic solution with methanol-water solution,
The second separating liquid is obtained, is successively 1:1,7:3,9:1, the methanol-water eluent of 1:0 with volume ratio to second separating liquid
Carry out gel column chromatography separation, volume ratio be 9:1 methanol-water eluent carry out gel column chromatography it is obtained after separation be containing
The eluent of the alkene terpene compound of structure shown in II, to the eluent of the alkene terpene compound containing structure shown in Formula II into
The alkene terpene compound with structure shown in Formula II, the second high pressure preparation condition are as follows: prepare column YMC- is prepared in the second high pressure of row
Pack ODS-A C18, flow velocity: 5mL/min；Mobile phase A: ultrapure water；Mobile phase B: methanol；It is isocratic: 0-50min, 45%B；
It is containing structure shown in formula III, V and VI that it is obtained after separation, which to carry out gel column chromatography, for 7:3 methanol-water eluent for volume ratio
Alkene terpene compound eluent, efficient liquid is carried out to the eluent of the alkene terpene compound containing structure shown in formula III, V and VI
Phase chromatographic isolation respectively obtains the alkene terpene compound with structure shown in formula III, V and VI, high-efficient liquid phase chromatogram condition are as follows: system
Standby column YMC-Pack ODS-A C18, flow velocity: 5mL/min；Mobile phase A: ultrapure water；Mobile phase B: methanol；Gradient: 0-
20min, 25%-50%B；20-50min, 50%-100%B；
In the present invention, the condition of the second medium pressure chromatography preparation is preferred are as follows: Ai Jieer Flash splitter:
CO140080-0, eluent: methanol-water solution carries out, methanol %, 25-50%, 10min；50-100%, 50min, flow velocity
30mL/min。
In the present invention, the specification for preparing column of second high pressure preparation is independently preferably 250 × 20mm, and 5 μm.
In the present invention, the alkene terpene compound of structure shown in Formula II is present in the component of 57~59min, shown in formula III
The alkene terpene compound of structure is present in the component of 60~61min, the alkene terpene compound of structure shown in Formula V be present in 52~
It is present in the component of 53min in the component of 54min with the alkene terpene compound of structure shown in Formula IV.
The present invention provides serial alkene terpene compound, structure is as follows:
The present invention also provides series alkene terpenoids made from the preparation method described in above-mentioned technical proposal or above-mentioned
Serial alkene terpenoid inhibits the application in bacterial drug in preparation.In the present invention, the preferably golden yellow grape of the bacterium
Coccus.
The present invention also provides series alkene terpenoids made from the preparation method described in above-mentioned technical proposal or above-mentioned
Serial alkene terpenoid inhibits the application in human pathogenic fungi's drug in preparation.In the present invention, the human disease is true
Bacterium preferred white candida albicans and Cryptococcus neoformans.
The present invention also provides series alkene terpenoids made from the preparation method described in above-mentioned technical proposal or above-mentioned
Serial alkene terpenoid inhibits the application in phytopathogenic fungi drug in preparation.In the present invention, the plant pathogenic is true
Bacterium preferably (apple) rotten pathogenic bacteria.
The present invention also provides series alkene terpenoids made from the preparation method described in above-mentioned technical proposal or above-mentioned
Serial alkene terpenoid preparation treating cancer drug in application.In the present invention, the cancer is by existing lung
Cancer, the specific application are preferably the application in the drug of preparation human lung cancer cell line A549.
In the present invention, the serial alkene terpenoid can be separately as drug, can also be with other drugs (such as fluorine
Health azoles, amphotericin B, nystatin) it is used in combination.In the present invention, the serial alkene terpenoid can be made various
Pharmaceutical dosage form (including tablet, capsule, spraying, effervescent tablet, ointment, injection) uses.
Serial alkene terpenoid provided by the invention and its preparation method and application is carried out below with reference to embodiment detailed
Thin explanation, but they cannot be interpreted as limiting the scope of the present invention.
Embodiment 1
(1) it is inoculated on 200mL culture medium from trametes robinioplila solid seed plate with 6 pieces of mycelia of transfer needle picking 5cm size
Seed culture is carried out, trametes robinioplila seed liquor is obtained；
(2) after the trametes robinioplila fungi is inoculated with 2 days, oyster mushroom is inoculated with and carries out seed culture, obtain oyster mushroom seed liquor；
(3) after oyster mushroom culture 5 days, the seed liquor of the trametes robinioplila is inoculated in oyster mushroom seed liquor and carries out co-cultivation 20
It；
Step (1) and (2) described seed culture medium component are as follows: glucose 10g/L, peptone 2g/L, potassium dihydrogen phosphate
1g/L, magnesium sulfate 0.5g/L
The cultivation temperature of the seed culture is 28 DEG C；
The seed culture carries out on shaking table, and the revolving speed of shaking table is 160rpm；The culture of co-cultivation condition and seed liquor
It is consistent.
50L co-culture media is taken, 1:1 is added ethyl acetate continuous extraction 3 times by volume, combining extraction liquid, vacuum rotary steam
Obtain medicinal extract 5g.On silicagel column (25 × 520mm, Tianjin Bonaaijieer Technology Co., Ltd, 200 mesh), petroleum ether-is used
Ethyl acetate (5:1,1:1), methylene chloride-methanol (20:1,10:1,5:1,1:1,0:1) system is as eluent, to medicinal extract
It is chromatographed, obtains 7 components, Mass Spectrometer Method discovery wherein contains Formulas I, IV institute in component 3 (methylene chloride: water=20:1)
Show alkene terpenoid, be spin-dried for component 3, obtains the thick component 1.57g of alkene terpenoid.Then to thick group of alkene terpenoid
Divide and carry out pressure separation (Ai Jieer Flash splitter: CO140080-0) in first, is eluted with methanol (MeOH)-aqueous systems
(MeOH%, 15-40%, 8min；40-100%, 82min；Flow velocity 30mL/min), Mass Spectrometer Method merges containing alkene shown in Formulas I, IV
The fraction of terpenoid, total 930mg.Then isolated and purified on gel column, with methanol-water (volume ratio 1:1,7:3,9:1,
1:0) system elutes, and each ratio eluent three times column volume elution, alkene terpenoid shown in Formulas I is present in 7:3 elution
In the eluent of ratio.Merge the fraction containing alkene terpenoid shown in Formulas I, it is then enterprising in high performance liquid chromatography (HPLC)
Row purifying, HPLC parameter are as follows: preparing column: YMC-Pack ODS-A C18 (250x20mm, 5 μm), flow velocity: 5mL/min；Stream
Dynamic phase A: ultrapure water；Mobile phase B: methanol；Gradient: 0-25min, 25%-40%B；25-60min, 40-100%B.Merging contains
The segmentation of same composition, Mass Spectrometer Method obtain the 10.3mg of alkene terpenoid shown in Formulas I.Gel elution liquid removes 7:3 and elutes ratio
Remaining is merged pressure separation (Ai Jieer Flash splitter: CO140080-0) in continuing, is washed with methanol-water solution by example
De- (MeOH%, 15-30%, 10min；30-70%, 82min；Flow velocity 30mL/min), Mass Spectrometer Method obtains IV substance of formula.
Using 600MHz NMR spectrum (NMR spectrometer) measurement proton magnetic resonance (PMR) (1H-NMR)、13C
Nuclear magnetic resonance (13C-NMR) terpenoid of structure alkene shown in Formulas I is detected, as illustrated in fig. 1 and 2, to structure shown in Formulas I
Alkene terpenoid carry out MS/MS analysis, result be Fig. 3 shown in, as seen from Figure 3, alkene terpenoid shown in Formulas I
Molecular weight [M+HCOO]-Molecular weight is 489.3451.The molecular weight is by high-resolution electrospray ionization mass spectrometry instrument (high-
Resolution electron sprayionizationmass spectrometer, HRESIMS) it adopts in the negative ion mode
What collection obtained, the molecular formula of the compound is C25H48O6。
MS/MS analysis is carried out to the terpenoid of structure alkene shown in formula IV, result is shown in Fig. 4, it can be seen from Fig. 4
The molecular weight [M+HCOO] of the terpenoid of structure alkene shown in formula IV-, molecular weight 471.2854.The molecular weight is by high-resolution
Rate electrospray ionization mass spectrometry instrument (high-resolution electron sprayionizationmass spectrometer,
HRESIMS it) collects in the negative ion mode, the molecular formula of the alkene terpenoid is C25H46O5。
Embodiment 2
Trametes robinioplila and oyster mushroom are co-cultured, condition such as embodiment 1 is co-cultured, obtains 50L co-culture media, by volume
1:3 is added ethyl acetate continuous extraction 3 times；Combining extraction liquid, vacuum rotary steam obtain medicinal extract 5g.In silicagel column (25 × 520mm, day
Saliva Beaune Ai Jieer Science and Technology Ltd., 300 mesh) on, use petroleum ether-ethyl acetate (5:1,1:1), methylene chloride-methanol
(20:1,10:1,5:1,1:1,0:1) system chromatographs medicinal extract as eluent, obtains 7 components, Mass Spectrometer Method hair
It is existing, wherein component is spin-dried for containing alkene terpenoid shown in Formula II, III, V and VI in component 4 (methylene chloride: water=10:1)
4, obtain the thick component 2.57g of alkene terpenoid.Then pressure separation (Ai Jie in first is carried out to the thick component of alkene terpenoid
That Flash splitter: CO140080-0), (MeOH%, 25-50%, 10min are eluted with methanol-water solution；50-
100%, 50min；Flow velocity 30mL/min), Mass Spectrometer Method merges the fraction containing alkene terpenoid shown in Formula II respectively, altogether
830mg, the fraction 980mg of alkene terpenoid shown in formula III, V and formula VI.Then it is isolated and purified on gel column respectively, with
The elution of methanol-water (volume ratio 1:1,7:3,9:1,1:0) system, each ratio eluent three times column volume elution, Mass Spectrometer Method
It was found that alkene terpenoid shown in II is present in the eluent of 7:3 and 9:1 elution ratio, alkene shown in formula III, V and formula VI
Terpenoid is all present in 7:3.Merge the fraction containing alkene terpenoid shown in Formula II, then in high performance liquid chromatography
(HPLC) it is purified on, HPLC parameter is as follows: preparing column: YMC-Pack ODS-AC18 (250x20mm, 5 μm), flow velocity:
5mL/min；Mobile phase A: ultrapure water；Mobile phase B: methanol；Gradient: 0-50min, 45%B.Merge the segmentation containing same composition,
Mass Spectrometer Method obtains the monomer 8.6mg of alkene terpenoid shown in Formula II.Containing alkene terpene shown in formula III, V and formula VI in gel
The eluent for closing object merges upper high performance liquid chromatography separation, high performance liquid chromatography separation condition are as follows: prepare column YMC-Pack
ODS-AC18 (250x20mm, 5 μm), flow velocity: 5mL/min；Mobile phase A: ultrapure water；Mobile phase B: methanol；Gradient: 0-
20min, 25%-50%B；20-50min, 50%-100%B.Merge detection and obtains alkene terpenoid 4.7mg shown in formula III
Monomer, compound V3.2mg and compound VI2.4mg.
Using 600MHz NMR spectrum (NMR spectrometer) measurement proton magnetic resonance (PMR) (1H-NMR)、13C
Nuclear magnetic resonance (13C-NMR) Formula II alkene terpenoid is detected, as shown in Figure 5 and Figure 6, to the terpene of structure alkene shown in Formula II
Class compound carry out MS/MS analysis, result be Fig. 7 shown in, as seen from Figure 7, the molecule of alkene terpenoid shown in Formula II
It measures [M-H]-Molecular weight is 441.324.The molecular weight is by high-resolution electrospray ionization mass spectrometry instrument (high-resolution
Electron spray ionization mass spectrometer, HRESIMS) collect in the negative ion mode,
The molecular formula of the compound is C25H46O6。
Using 600MHz NMR spectrum (NMR spectrometer) measurement proton magnetic resonance (PMR) (1H-NMR)、13C
Nuclear magnetic resonance (13C-NMR) formula III alkene terpenoid is detected, as shown in Fig. 8 and Fig. 9, to structure alkene shown in formula III
Terpenoid carry out MS/MS analysis, result be Figure 10 shown in, as seen from Figure 10, alkene terpenoid shown in formula III
Molecular weight [M-H]-Molecular weight is 439.308.The molecular weight is by high-resolution electrospray ionization mass spectrometry instrument (high-
Resolution electron sprayionizationmass spectrometer, HRESIMS) it adopts in the negative ion mode
What collection obtained, the molecular formula of the compound is C25H44O6。
From1HNMR and13It is seen on C NMR, compound III and the structure of compound II are much like, and most peak does not become
To change, but 2 C signal δ=129.1 become δ=40.62,3 C signal δ=143.2 become δ=34.58,4 C signal δ=
28.2 become δ=23.92, and 2'C signal δ=12.5 become δ=17.76；3 H signal δ=6.75 become δ=1.57,4 H
Signal δ=2.31 become δ=1.29, and 2'H signal δ=1.8 become δ=1.12, and m/z 441.324 divides than m/z 439.308
Son amount more 2.Therefore, judge that m/z 441.324 is the hydrogenation products of m/z 439.308, in conjunction with1H NMR and13C NMR determines m/
Hydrogenation reduction has occurred in 439.308 left side double bond of z.
LC-MS analysis is carried out to structure alkene terpenoid shown in Formula V, VI, as a result respectively Figure 11, shown in 12,
The molecular weight of the alkene terpenoid shown in Formula V it can be seen from Figure 11 and 12 and VI is [M+HCOO]-437.34, molecular formula
It is C25H46O5, alkene terpenoid shown in Formula V and VI is that reduction reaction occurs on the basis of Formula II to obtain.
Micro susceptibility detects activity experiment
Using 96 orifice plate Dilution above compounds to Candida albicans, Cryptococcus neoformans, Staphylococcus aureus
Bacterium, (apple) rotten pathogenic bacteria and human lung cancer cell line A549 minimum inhibitory concentration.Extracting waste candida albicans, Cryptococcus neoformans
It is inoculated in YPD fluid nutrient medium that (for S. aureus Inoculate in LB culture medium, (apple) rotten pathogenic bacteria is inoculated in PDA
In culture medium, human lung cancer cell line A549 is inoculated in RPMI1640 culture medium), 35 DEG C of constant temperature incubations 12 hours (cancer cell in
5%CO2, 37 DEG C of culture 72h；(apple) rotten pathogenic bacteria culture 48h), when strain OD600 value is 0.8-1,400 μ L is taken to try
Bacterium solution in pipe is centrifuged two minutes in centrifuge with 6000rpm, in the centrifuge tube of sterilized 1.5ml then in ultra-clean work
Make to discard supernatant in platform, retains precipitating, the precipitating after centrifugation is suspended again with 0.85% physiological saline, is diluted to
OD625=0.08-0.1.Clump count at this time is 1-5 × 106Cfu, with 1-5 × 106The strain concentration of cfu is as initial dense
Degree, dilutes 10 by 1:50,1:20 with RPMI-1640 culture medium again3Times, obtaining clump count is 1-5 × 103Cfu, in this, as reality
Bacteria concentration used is tested to be tested.Amphotericin B, nystatin, penicillin is taken to compare, the substance of purification is as medicine
2 times of gradient dilutions of product are tested.Equivalent DMSO is added in blank well.It is small that 96 orifice plates are placed in culture 12 in constant incubator
When, it is compared after taking-up with blank control, three times, bacteriostasis rate is calculated according to the following formula in parallel testing, takes 80% growth of inhibition
Drug be its minimum inhibitory concentration.The results are shown in Table 1 for it, as can be seen from Table 1, series alkene terpene produced by the present invention
Compound has certain rejection ability to Candida albicans, Cryptococcus neoformans and staphylococcus aureus, and to (apple) corruption
Rotten germ and human lung cancer cell line A549 have good inhibitory effect.
1 MIC statistical form of table
Unit: μ g/mL
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications
It should be regarded as protection scope of the present invention.
Claims (10)
1. the preparation method of serial alkene terpene compound, comprising the following steps:
(1) trametes robinioplila is inoculated on seed culture medium and is cultivated, obtain trametes robinioplila seed liquor, the deposit number of the trametes robinioplila is
CGMCC No.15274；
Oyster mushroom is inoculated on seed culture medium and is cultivated, oyster mushroom seed liquor is obtained；
(2) the trametes robinioplila seed liquor that the step (1) obtains is mixed with oyster mushroom seed liquor and is co-cultured, obtain co-culture media；
(3) it is extracted with the co-culture media that ethyl acetate obtains the step (2), removes solvent after obtaining extract liquor, obtain
To medicinal extract；
With volume ratio be successively 5:1 and the petroleum ether-ethyl acetate eluent of 1:1, volume ratio 20:1,10:1,5:1,1:1 and
The methylene chloride-methanol eluent of 0:1, chromatographs medicinal extract, respectively obtains 7 chromatographic solutions, is successively defined as the first~the
Seven chromatographic solutions；
The first medium pressure chromatography preparation is carried out with methanol-water solution to the third chromatographic solution, the first separating liquid is obtained, to described the
One separating liquid successively carries out gel column chromatography separation, volume with the methanol-water eluent that volume ratio is 1:1,7:3,9:1 and 1:0
It is the alkene terpene compound containing structure shown in Formulas I than it is obtained after separation to carry out gel column chromatography for 7:3 methanol-water eluent
Eluent carries out the first high pressure preparation to the eluent of the alkene terpene compound containing structure shown in I, obtains with Formulas I institute
Show the alkene terpene compound of structure, the first high pressure preparation condition: chromatographic column: YMC-Pack ODS-A C18, flow velocity: 5mL/min；Stream
Dynamic phase A: ultrapure water；Mobile phase B: methanol；Gradient: 0-25min, 25%-40%B；25-60min, 40-100%B；Volume ratio is
It is the alkene terpene containing structure shown in formula IV that it is obtained after separation, which to carry out gel column chromatography, for the methanol-water eluent of 1:1,9:1 and 1:0
The eluent of compound purifies the eluent of the alkene terpene compound containing structure shown in formula IV, obtains with formula
The alkene terpene compound of structure shown in IV；
The second medium pressure chromatography preparation is carried out with methanol-water solution to the 4th chromatographic solution, the second separating liquid is obtained, to described the
Two separating liquids successively carry out gel column chromatography separation, volume with the methanol-water eluent that volume ratio is 1:1,7:3,9:1 and 1:0
It is the alkene terpene compound containing structure shown in II than it is obtained after separation to carry out gel column chromatography for 9:1 methanol-water eluent
Eluent carries out the second high pressure to the eluent of the alkene terpene compound containing structure shown in Formula II and is prepared with Formula II
The alkene terpene compound of shown structure, the second high pressure preparation condition are as follows: prepare column YMC-Pack ODS-A C18, flow velocity: 5mL/
min；Mobile phase A: ultrapure water；Mobile phase B: methanol；It is isocratic: 0-50min, 45%B；Volume ratio be 7:3 methanol-water eluent into
It is the eluent of the alkene terpene compound containing structure shown in formula III, V and VI that row gel column chromatography is obtained after separation, to containing
The eluent of the alkene terpene compound of structure shown in formula III, V and VI carry out high performance liquid chromatography separation respectively obtain with formula III,
The alkene terpene compound of structure shown in V and VI, high-efficient liquid phase chromatogram condition are as follows: prepare column YMC-Pack ODS-A C18, flow velocity:
5mL/min；Mobile phase A: ultrapure water；Mobile phase B: methanol；Gradient: 0-20min, 25%-50%B；20-50min, 50%-
100%B；
2. preparation method according to claim 1, which is characterized in that seed culture medium independently wraps in the step (1)
Include the component of following concentration: 8~12g/L of glucose, 1~3g/L of peptone, 0.8~1.2g/L of potassium dihydrogen phosphate, magnesium sulfate 0.3
~0.5g/L, the water of surplus.
3. preparation method according to claim 1 or 2, which is characterized in that the amount ratio of the trametes robinioplila and seed culture medium
To contain the trametes robinioplila mycelia that 6~8 block specifications are 5cm size in 200mL culture medium；The amount ratio of the oyster mushroom and seed culture medium is
Contain the hypha of Pleurotus ostreatus that 8~10 block specifications are 5cm size in 200mL culture medium.
4. preparation method according to claim 3, which is characterized in that the inoculum concentration of trametes robinioplila seed liquor in the step (2)
It is 50~70%.
5. preparation method according to claim 1, which is characterized in that cultivate in the step (1) and trained altogether in step (2)
Feeding temperature independently is 24~28 DEG C.
6. preparation method according to claim 1 or 5, which is characterized in that the incubation time of trametes robinioplila is in the step (1)
5~8, the incubation time of oyster mushroom is 4~6 days.
7. preparation method according to claim 1 or 5, which is characterized in that the time co-cultured in the step (2) is 15
~25 days.
8. serial alkene terpene compound, have Formulas I~Formula IV it is any shown in structure:
9. described in series alkene terpenoid made from preparation method described in claim 1~7 any one or claim 8
Serial alkene terpenoid inhibit bacterium, the application in human pathogenic fungi and phytopathogenic fungi drug in preparation.
10. series alkene terpenoid made from preparation method described in claim 1~7 any one or claim 8 institute
Application of the serial alkene terpenoid stated in the drug of preparation treating cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810494741.8A CN108516923B (en) | 2018-05-22 | 2018-05-22 | A series of alkene terpenoids and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810494741.8A CN108516923B (en) | 2018-05-22 | 2018-05-22 | A series of alkene terpenoids and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108516923A CN108516923A (en) | 2018-09-11 |
| CN108516923B true CN108516923B (en) | 2019-06-25 |
Family
ID=63426621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810494741.8A Active CN108516923B (en) | 2018-05-22 | 2018-05-22 | A series of alkene terpenoids and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108516923B (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1173898A (en) * | 1995-02-08 | 1998-02-18 | 株式会社植物防御***研究所 | Antifungal torpene compounds and process for produing the same |
| CN1061850C (en) * | 1996-05-10 | 2001-02-14 | 南京中医药大学 | Auricularia in sophorae and use in medicine |
| CN100395241C (en) * | 2006-05-26 | 2008-06-18 | 中国科学院南海海洋研究所 | Degradeable furan sesterterpenes keratinous spongistatin, and its preparing method and use |
| ITMI20121109A1 (en) * | 2012-06-25 | 2013-12-26 | Rode Pharma S R L | COMPOSITION INCLUDING GASCARDIC ACID OR ITS DERIVATIVE AND ITS USE AS ADJUSTMENT FOR ANTIBIOTICS |
| WO2016193755A1 (en) * | 2015-06-04 | 2016-12-08 | Synshark Llc | Process for recovering terpenes from plant material |
-
2018
- 2018-05-22 CN CN201810494741.8A patent/CN108516923B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108516923A (en) | 2018-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102367424B (en) | Coriobacterium sp. AUH-Julong21 and use of coriobacterium sp. AUH-Julong21 in liquiritigenin conversion | |
| CN101190258A (en) | Total sesquiterpene lactone extract containing rich parthenolide and preparation method and application thereof | |
| US5057493A (en) | Novel antibiotics r106 | |
| CN103172507B (en) | Ophiobollin sesterterpine compound as well as preparation method and application thereof | |
| CN108329280A (en) | A kind of natural Rakicidins classes compound R akicidin I and its extracting method | |
| CN101720772B (en) | Macrolide composition for preventing and controlling fungal disease of crop and preparation process thereof | |
| CN107974412B (en) | Penicillium roqueforti for preparing anti-inflammatory active compound peniroquesine A and application thereof | |
| CN108530379A (en) | A kind of natural Rakicidins classes compound R akicidin G and its extracting method | |
| CN108586380A (en) | A kind of natural Rakicidins classes compound R akicidin H and its extracting method | |
| CN103214547B (en) | A kind of compound and the application in preparation antibacterials thereof | |
| CN110218200B (en) | Cyclic depsipeptide compound in mangrove endophytic fungi and preparation method and application thereof | |
| CN108516923B (en) | A series of alkene terpenoids and its preparation method and application | |
| CN103408550A (en) | 2,5-diketopiperazine dipeptide derived from lysobacter enzymogenes as well as preparation method and application thereof | |
| CN107382863B (en) | Trienomycin compound, preparation method and application for treating prostatic cancer | |
| CN110229131B (en) | Benzopyrone derivative derived from cerasus humilis endophytic fungi as well as preparation method and application thereof | |
| CN107954839A (en) | A kind of antiinflammatory active compound peniroquesine A and its preparation method and application | |
| CN102617707B (en) | Preparation method of new homologue 2-methyl-actinomycin D of actinomycin D | |
| CN102452916B (en) | New aromatic polyketones, extraction method and application thereof | |
| CN102531906B (en) | Application of natural compound P21 in inhibition of reproductive growth of tumor cell | |
| CN105837590A (en) | Compound with anti-Candida albicans activity, preparation method and application thereof | |
| JP3719689B2 (en) | Novel substance triprostatin, process for producing the same, cell cycle inhibitor and antitumor agent | |
| CN109553565B (en) | Two new alkaloids, preparation method thereof and application thereof in preparation of MRSA-resistant antibacterial agent | |
| CN103113376A (en) | Alkaloid, and preparation method and application thereof | |
| CN115710172B (en) | Diterpenoid compound in euphorbia pekinensis, and extraction method and application thereof | |
| CN115286682B (en) | 3-O-arabinosyl mesitylene Liu Suanzao glycoside and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191101 Address after: No. 1-7-101 and 301, hekechuangyuan, north side of Jinyong highway, Shuangkou Town, Beichen District, Tianjin Patentee after: Tianjin Mass Spectrometry Biotechnology Co., Ltd. Address before: 301700 Tianjin Wuqing District Wuqing Development Zone Fuyuan Road and Quanwang Road junction northeast of building 1, 1102-14 (centralized office area) Patentee before: TIANJIN HANRONG BIOTECHNOLOGY CO., LTD. |
|
| TR01 | Transfer of patent right |